Provexis Announces Update on

RNS Number : 5682A

Provexis PLC

12 October 2009

 



12 October 2009

Provexis plc

("Provexis" or the "Company")

Provexis Announces Update on Human Trial

Provexis plc (PXS.L), the life-science business that discovers, develops and licenses scientifically-proven functional food, medical food and dietary supplement technologies today announces an update on the human trial comparing the effects of its Fruitflow® anti-thrombotic functional food technology with aspirin.

Fruitflow® is designed as a dietary supplement which will inhibit several pathways of platelet aggregation without side effects.  Aspirin is a drug which targets one specific platelet aggregation pathway, and is not recommended for use by the population at large for cardiovascular disease prevention partly due to its well known side effects including gastric bleeding.  In addition, a significant percentage of users show some resistance to its effects.

In the current trial, Fruitflow® showed up to 28% reduction from baseline platelet aggregation occurring through three different biological pathways, while aspirin showed up to 60% reduction in one of these pathways, but no effect on the other two.  The broader antiplatelet effect of Fruitflow® reflects the Company's aim to provide a daily dietary supplement with a significant effect on blood flow, but without suppressing platelet aggregation completely.

The trial compares the effects of both Fruitflow® and aspirin on a single dose basis over a five hour time course.  At this stage around 40% of subjects have completed the trial, which will continue until the end of the year.  The trial is being carried out by Provexis at the Rowett Institute of Nutrition and Health, part of the University of Aberdeen, with independent statistical analysis by BIOSS.

Stephen Moon, CEO of Provexis commented:

"We are very pleased that these interim results highlight the potential of Fruitflow as an effective and safe dietary supplement which significantly reduces platelet aggregation in all users.  This is our tenth placebo controlled human trial and together with the recent European Food Safety Authority endorsement of the science it further highlights the potential of Fruitflow."

For further information please contact:

Provexis plc                                 Tel:   [phone]

Stephen Moon, Chief Executive

Ian Ford, Finance Director

Arbuthnot Securities                      Tel:   [phone]

Tom Griffiths/Alasdair Younie

ENDS

 

END

 

 

NRACKCKDPBDDQKK